Quarterly Holdings Report
for
Fidelity® MSCI Health Care Index ETF
April 30, 2025
T05-NPRT3-0625
1.9584810.111

Schedule of Investments April 30, 2025 (Unaudited)
Showing Percentage of Net Assets
Common Stocks – 99.7%
    Shares Value
BIOTECHNOLOGY – 20.0% 
Biotechnology – 20.0%
89bio, Inc. (a) 46,328 $371,551
AbbVie, Inc. 774,740 151,151,774
ACADIA Pharmaceuticals, Inc. (a) 47,759 697,281
ADMA Biologics, Inc. (a) 103,577 2,465,133
Agios Pharmaceuticals, Inc. (a) 22,514 668,441
Akero Therapeutics, Inc. (a) 21,174 965,746
Akouos, Inc. (a) 11,863 2,135
Alkermes PLC (a) 67,363 1,938,034
Alnylam Pharmaceuticals, Inc. (a) 56,542 14,884,116
Altimmune, Inc. (a) 30,849 161,957
Amgen, Inc. 235,658 68,557,625
Amicus Therapeutics, Inc. (a) 99,203 761,879
AnaptysBio, Inc. (a) 7,549 167,739
Anavex Life Sciences Corp. (a) 37,156 352,982
Annexon, Inc. (a) 29,991 55,783
Apellis Pharmaceuticals, Inc. (a) 29,990 576,108
Apogee Therapeutics, Inc. (a) 9,813 385,160
Arbutus Biopharma Corp. (a) 61,909 219,777
Arcellx, Inc. (a) 14,356 932,422
Arcturus Therapeutics Holdings, Inc. (a) 10,419 133,467
Arcus Biosciences, Inc. (a) 29,905 261,669
Arcutis Biotherapeutics, Inc. (a) 45,504 678,465
Ardelyx, Inc. (a) 106,702 587,395
ArriVent Biopharma, Inc. (a) 5,852 124,414
Arrowhead Pharmaceuticals, Inc. (a) 48,843 678,429
ARS Pharmaceuticals, Inc. (a) 17,921 250,356
Astria Therapeutics, Inc. (a) 11,134 57,451
Aurinia Pharmaceuticals, Inc. (a) 53,072 437,313
Avidity Biosciences, Inc. (a) 36,593 1,194,761
Beam Therapeutics, Inc. (a) 39,023 777,728
BioCryst Pharmaceuticals, Inc. (a) 85,820 759,507
Biogen, Inc. (a) 63,886 7,735,317
Biohaven Ltd. (a) 37,671 833,283
BioMarin Pharmaceutical, Inc. (a) 83,418 5,312,892
Blueprint Medicines Corp. (a) 27,943 2,500,898
Bridgebio Pharma, Inc. (a) 54,155 2,077,386
Capricor Therapeutics, Inc. (a) 17,931 227,724
CareDx, Inc. (a) 23,155 390,856
Cargo Therapeutics, Inc. (a) 8,026 36,679
Catalyst Pharmaceuticals, Inc. (a) 47,349 1,150,107
Celldex Therapeutics, Inc. (a) 26,092 543,496
CG oncology, Inc. (a) 17,871 481,445
Chinook Therapeutics, Inc. (a) 24,218 0
Cogent Biosciences, Inc. (a) 31,470 163,959
Crinetics Pharmaceuticals, Inc. (a) 36,569 1,221,039
CRISPR Therapeutics AG (a) 35,766 1,383,071
Cullinan Therapeutics, Inc. (a) 13,919 115,249
Cytokinetics, Inc. (a) 49,391 2,115,910

    Shares Value
Day One Biopharmaceuticals, Inc. (a) 25,318 $196,974
Denali Therapeutics, Inc. (a) 56,110 934,231
Disc Medicine, Inc. (a) 8,084 399,511
Dynavax Technologies Corp. (a) 51,373 603,633
Dyne Therapeutics, Inc. (a) 26,763 315,536
Entrada Therapeutics, Inc. (a) 7,990 72,949
Erasca, Inc. (a) 84,048 122,710
Exact Sciences Corp. (a) 81,208 3,706,333
Exelixis, Inc. (a) 112,797 4,416,003
Geron Corp. (a) 223,722 315,448
Gilead Sciences, Inc. 546,390 58,212,391
GRAIL, Inc. (a) 13,251 457,093
Halozyme Therapeutics, Inc. (a) 55,654 3,418,269
Humacyte, Inc. (a) 53,780 77,981
Ideaya Biosciences, Inc. (a) 34,509 694,666
ImmunityBio, Inc. (a) 92,823 232,986
Immunome, Inc. (a) 28,546 250,919
Immunovant, Inc. (a) 29,478 476,070
Incyte Corp. (a) 71,991 4,510,956
Insmed, Inc. (a) 74,459 5,361,048
Intellia Therapeutics, Inc. (a) 42,137 373,755
Ionis Pharmaceuticals, Inc. (a) 61,962 1,902,853
Iovance Biotherapeutics, Inc. (a) 92,768 333,037
Ironwood Pharmaceuticals, Inc. (a) 61,930 57,737
Janux Therapeutics, Inc. (a) 18,517 614,764
Kiniksa Pharmaceuticals International PLC (a) 15,968 430,657
Krystal Biotech, Inc. (a) 9,410 1,598,571
Kura Oncology, Inc. (a) 19,953 130,892
Kymera Therapeutics, Inc. (a) 16,911 579,540
Madrigal Pharmaceuticals, Inc. (a) 5,781 1,930,334
MannKind Corp. (a) 118,580 597,643
Merus NV (a) 20,841 948,474
MiMedx Group, Inc. (a) 50,452 347,110
Mirum Pharmaceuticals, Inc. (a) 15,968 693,810
Moderna, Inc. (a) 143,764 4,103,025
MoonLake Immunotherapeutics (a) 9,648 405,988
Myriad Genetics, Inc. (a) 39,640 293,732
Natera, Inc. (a) 54,981 8,298,282
Neurocrine Biosciences, Inc. (a) 44,479 4,789,944
Newamsterdam Pharma Co. NV (a) 15,969 305,487
Novavax, Inc. (a) 62,904 419,570
Nurix Therapeutics, Inc. (a) 26,379 304,150
Nuvalent, Inc. Class A (a) 16,012 1,228,921
ORIC Pharmaceuticals, Inc. (a) 14,660 83,709
Praxis Precision Medicines, Inc. (a) 5,947 223,845
Protagonist Therapeutics, Inc. (a) 19,836 908,886
Prothena Corp. PLC (a) 15,190 139,748
PTC Therapeutics, Inc. (a) 30,592 1,524,705
Radius Health, Inc. (a) 20,244 0
 
 Quarterly Report 2

Common Stocks – continued
    Shares Value
BIOTECHNOLOGY – continued
Biotechnology – continued
Recursion Pharmaceuticals, Inc. Class A (a) 108,041 $603,949
Regeneron Pharmaceuticals, Inc. 47,379 28,368,650
Relay Therapeutics, Inc. (a) 50,830 169,264
Replimune Group, Inc. (a) 22,989 224,832
Revolution Medicines, Inc. (a) 62,563 2,526,294
Rhythm Pharmaceuticals, Inc. (a) 20,193 1,316,382
Rocket Pharmaceuticals, Inc. (a) 34,110 260,259
Roivant Sciences Ltd. (a) 159,045 1,848,103
Sana Biotechnology, Inc. (a) 51,005 96,909
Sarepta Therapeutics, Inc. (a) 37,741 2,355,038
Savara, Inc. (a) 43,023 137,674
Scholar Rock Holding Corp. (a) 28,710 944,846
Soleno Therapeutics, Inc. (a) 11,324 847,715
SpringWorks Therapeutics, Inc. (a) 25,952 1,201,578
Spyre Therapeutics, Inc. (a) 15,233 231,999
Stoke Therapeutics, Inc. (a) 14,947 145,883
Syndax Pharmaceuticals, Inc. (a) 33,244 470,403
TG Therapeutics, Inc. (a) 64,601 2,939,992
Tourmaline Bio, Inc. (a) 4,471 76,946
Travere Therapeutics, Inc. (a) 35,738 743,708
Twist Bioscience Corp. (a) 25,839 990,150
Tyra Biosciences, Inc. (a) 6,640 68,392
Ultragenyx Pharmaceutical, Inc. (a) 36,223 1,411,973
United Therapeutics Corp. (a) 18,580 5,631,412
Vaxcyte, Inc. (a) 49,152 1,761,608
Vera Therapeutics, Inc. (a) 20,060 468,802
Veracyte, Inc. (a) 33,775 1,030,137
Vericel Corp. (a) 21,422 814,464
Vertex Pharmaceuticals, Inc. (a) 112,905 57,525,097
Verve Therapeutics, Inc. (a) 26,887 152,449
Viking Therapeutics, Inc. (a) 44,339 1,280,067
Vir Biotechnology, Inc. (a) 40,126 245,571
Viridian Therapeutics, Inc. (a) 23,647 320,417
Xencor, Inc. (a) 25,832 284,669
Xenon Pharmaceuticals, Inc. (a) 28,609 1,092,864
Zymeworks, Inc. (a) 18,114 235,663
      514,714,944
Pharmaceuticals – 0.0%
LENZ Therapeutics, Inc. (a) 5,335 152,127
TOTAL BIOTECHNOLOGY 514,867,071
HEALTH CARE EQUIPMENT & SUPPLIES – 21.7% 
Health Care Equipment – 20.5%
Abbott Laboratories 760,418 99,424,653
Alphatec Holdings, Inc. (a) 45,853 503,466
Artivion, Inc. (a) 16,553 392,141
AtriCure, Inc. (a) 21,418 640,612
Axogen, Inc. (a) 18,307 297,855
Baxter International, Inc. 223,855 6,977,560

    Shares Value
Becton Dickinson & Co. 127,147 $26,330,872
Boston Scientific Corp. (a) 646,158 66,470,273
Butterfly Network, Inc. (a) 61,325 143,501
Ceribell, Inc. (a) 5,495 88,415
CONMED Corp. 13,793 677,374
Dexcom, Inc. (a) 171,242 12,223,254
Edwards Lifesciences Corp. (a) 258,578 19,520,053
Enovis Corp. (a) 24,455 845,898
Envista Holdings Corp. (a) 76,353 1,227,756
GE HealthCare Technologies, Inc. 200,303 14,087,310
Glaukos Corp. (a) 24,219 2,282,641
Globus Medical, Inc. Class A (a) 49,877 3,579,672
Hologic, Inc. (a) 99,429 5,786,768
IDEXX Laboratories, Inc. (a) 35,901 15,532,568
Inspire Medical Systems, Inc. (a) 13,111 2,076,520
Insulet Corp. (a) 30,770 7,762,963
Integer Holdings Corp. (a) 14,706 1,857,515
Integra LifeSciences Holdings Corp. (a) 30,431 498,764
Intuitive Surgical, Inc. (a) 156,161 80,547,844
iRadimed Corp. 3,219 168,708
iRhythm Technologies, Inc. (a) 13,631 1,457,018
LeMaitre Vascular, Inc. 8,958 812,849
LivaNova PLC (a) 23,670 875,790
Masimo Corp. (a) 19,933 3,208,416
Medtronic PLC 562,173 47,649,783
Novocure Ltd. (a) 44,906 814,595
Omnicell, Inc. (a) 20,343 635,922
Orthofix Medical, Inc. (a) 14,513 201,876
Penumbra, Inc. (a) 16,060 4,703,010
PROCEPT BioRobotics Corp. (a) 22,520 1,215,630
Pulse Biosciences, Inc. (a) 5,389 91,721
QuidelOrtho Corp. (a) 29,348 815,581
ResMed, Inc. 64,353 15,225,276
SI-BONE, Inc. (a) 16,569 226,167
STERIS PLC 43,269 9,724,275
Stryker Corp. 150,420 56,245,046
Tandem Diabetes Care, Inc. (a) 28,883 486,679
Teleflex, Inc. 20,353 2,789,379
TransMedics Group, Inc. (a) 14,660 1,348,867
Varex Imaging Corp. (a) 17,526 145,816
Zimmer Biomet Holdings, Inc. 87,278 8,993,998
      527,612,650
Health Care Supplies – 1.2%
Align Technology, Inc. (a) 31,151 5,398,468
Avanos Medical, Inc. (a) 20,107 252,343
Bioventus, Inc. Class A (a) 15,657 114,453
Cooper Cos., Inc. (a) 87,505 7,146,533
Dentsply Sirona, Inc. 86,806 1,206,603
Embecta Corp. 24,537 299,106
Establishment Labs Holdings, Inc. (a) 8,985 272,695
3 Quarterly Report 

Schedule of Investments (Unaudited)continued
Common Stocks – continued
    Shares Value
HEALTH CARE EQUIPMENT & SUPPLIES – continued
Health Care Supplies – continued
Haemonetics Corp. (a) 21,961 $1,383,982
ICU Medical, Inc. (a) 10,118 1,382,018
Lantheus Holdings, Inc. (a) 30,599 3,192,700
Merit Medical Systems, Inc. (a) 25,590 2,416,976
Neogen Corp. (a) 89,680 452,884
OrthoPediatrics Corp. (a) 7,399 154,047
RxSight, Inc. (a) 15,378 226,364
Solventum Corp. (a) 64,267 4,249,334
STAAR Surgical Co. (a) 16,748 305,818
UFP Technologies, Inc. (a) 3,360 700,694
      29,155,018
TOTAL HEALTH CARE EQUIPMENT & SUPPLIES 556,767,668
HEALTH CARE PROVIDERS & SERVICES – 19.6% 
Health Care Distributors – 3.1%
AdaptHealth Corp. (a) 37,816 321,814
Cardinal Health, Inc. 106,104 14,991,434
Cencora, Inc. 76,262 22,319,600
Henry Schein, Inc. (a) 54,634 3,549,571
McKesson Corp. 55,659 39,673,179
Owens & Minor, Inc. (a) 30,973 218,669
      81,074,267
Health Care Facilities – 2.1%
Acadia Healthcare Co., Inc. (a) 40,530 948,402
Brookdale Senior Living, Inc. (a) 81,405 534,017
Concentra Group Holdings Parent, Inc. 50,242 1,092,764
Encompass Health Corp. 44,104 5,159,727
Ensign Group, Inc. 25,101 3,237,778
HCA Healthcare, Inc. 83,286 28,740,333
National HealthCare Corp. 5,760 544,262
PACS Group, Inc. (a) 20,329 195,768
Select Medical Holdings Corp. 48,591 886,300
Surgery Partners, Inc. (a) 30,238 663,724
Tenet Healthcare Corp. (a) 41,775 5,971,736
U.S. Physical Therapy, Inc. 6,601 469,397
Universal Health Services, Inc. Class B 25,727 4,555,480
      52,999,688
Health Care Services – 4.7%
Addus HomeCare Corp. (a) 7,923 828,350
agilon health, Inc. (a) 138,767 591,147
Amedisys, Inc. (a) 14,273 1,354,508
AMN Healthcare Services, Inc. (a) 16,465 336,380
Astrana Health, Inc. (a) 20,051 624,990
Aveanna Healthcare Holdings, Inc. (a) 21,094 97,243
BrightSpring Health Services, Inc. (a) 26,184 459,005

    Shares Value
Castle Biosciences, Inc. (a) 11,835 $237,292
Chemed Corp. 6,243 3,630,367
Cigna Group 121,941 41,464,818
CorVel Corp. (a) 12,351 1,343,295
Cross Country Healthcare, Inc. (a) 12,019 162,857
CVS Health Corp. 551,711 36,804,641
DaVita, Inc. (a) 19,770 2,798,443
Fulgent Genetics, Inc. (a) 9,602 166,595
GeneDx Holdings Corp. (a) 7,229 483,259
Guardant Health, Inc. (a) 54,511 2,574,555
Hims & Hers Health, Inc. (a) 78,261 2,590,439
Labcorp Holdings, Inc. 36,670 8,837,837
LifeStance Health Group, Inc. (a) 58,499 384,338
NeoGenomics, Inc. (a) 55,697 356,182
OPKO Health, Inc. (a) 151,815 209,505
Option Care Health, Inc. (a) 74,471 2,406,158
Pediatrix Medical Group, Inc. (a) 37,871 487,778
Pennant Group, Inc. (a) 15,646 400,850
Premier, Inc. Class A 42,113 857,000
Privia Health Group, Inc. (a) 42,255 992,147
Quest Diagnostics, Inc. 48,932 8,720,661
RadNet, Inc. (a) 27,721 1,452,026
      121,652,666
Managed Health Care – 9.7%
Alignment Healthcare, Inc. (a) 42,402 751,363
Centene Corp. (a) 221,344 13,247,438
Clover Health Investments Corp. (a) 171,534 583,216
Elevance Health, Inc. 101,672 42,761,210
HealthEquity, Inc. (a) 38,085 3,264,646
Humana, Inc. 52,787 13,842,863
Molina Healthcare, Inc. (a) 25,067 8,197,160
Progyny, Inc. (a) 31,707 724,188
UnitedHealth Group, Inc. 403,468 166,002,874
      249,374,958
TOTAL HEALTH CARE PROVIDERS & SERVICES 505,101,579
HEALTH CARE TECHNOLOGY – 0.9% 
Health Care Technology – 0.9%
Certara, Inc. (a) 56,442 782,286
Definitive Healthcare Corp. (a) 22,128 60,188
Doximity, Inc. Class A (a) 47,729 2,714,826
Evolent Health, Inc. Class A (a) 43,218 426,130
GoodRx Holdings, Inc. Class A (a) 40,181 186,038
HealthStream, Inc. 10,591 356,175
Phreesia, Inc. (a) 24,152 602,834
Schrodinger, Inc. (a) 27,492 704,620
Simulations Plus, Inc. 7,329 251,751
Teladoc Health, Inc. (a) 74,394 534,893
Veeva Systems, Inc. Class A (a) 67,616 15,801,183
 
 Quarterly Report 4

Common Stocks – continued
    Shares Value
HEALTH CARE TECHNOLOGY – continued
Health Care Technology – continued
Waystar Holding Corp. (a) 30,154 $1,120,824
TOTAL HEALTH CARE TECHNOLOGY 23,541,748
LIFE SCIENCES TOOLS & SERVICES – 8.4% 
Life Sciences Tools & Services – 8.4%
10X Genomics, Inc. Class A (a) 41,440 342,709
Adaptive Biotechnologies Corp. (a) 45,069 331,708
Agilent Technologies, Inc. 125,207 13,472,273
Avantor, Inc. (a) 298,379 3,875,943
Azenta, Inc. (a) 18,022 474,699
BioLife Solutions, Inc. (a) 16,473 397,164
Bio-Rad Laboratories, Inc. Class A (a) 8,558 2,088,837
Bio-Techne Corp. 69,721 3,510,452
Bruker Corp. 46,346 1,856,621
Charles River Laboratories International, Inc. (a) 22,355 2,651,750
Cytek Biosciences, Inc. (a) 50,418 187,051
Danaher Corp. 284,991 56,807,256
Fortrea Holdings, Inc. (a) 38,076 237,213
Illumina, Inc. (a) 69,720 5,410,272
IQVIA Holdings, Inc. (a) 79,575 12,339,695
Maravai LifeSciences Holdings, Inc. Class A (a) 49,347 99,681
Medpace Holdings, Inc. (a) 11,611 3,580,716
Mesa Laboratories, Inc. 2,437 280,864
Mettler-Toledo International, Inc. (a) 9,250 9,902,773
OmniAb, Inc. (a) 3,335 7,170
OmniAb, Inc. (a) 3,335 6,370
Pacific Biosciences of California, Inc. (a) 103,826 115,247
Repligen Corp. (a) 23,341 3,220,825
Revvity, Inc. 53,337 4,983,276
Sotera Health Co. (a) 68,021 782,242
Standard BioTools, Inc. (a) 95,587 106,102
Thermo Fisher Scientific, Inc. 167,698 71,942,442
Waters Corp. (a) 26,043 9,055,932
West Pharmaceutical Services, Inc. 31,752 6,708,880
TOTAL LIFE SCIENCES TOOLS & SERVICES 214,776,163
PHARMACEUTICALS – 29.1% 
Pharmaceuticals – 29.1%
Amneal Pharmaceuticals, Inc. (a) 60,822 465,897
Amphastar Pharmaceuticals, Inc. (a) 16,856 411,455
ANI Pharmaceuticals, Inc. (a) 7,517 532,354
Arvinas, Inc. (a) 20,804 200,134
Avadel Pharmaceuticals PLC (a) 37,818 336,202
Axsome Therapeutics, Inc. (a) 13,833 1,553,308
Bristol-Myers Squibb Co. 889,195 44,637,589

    Shares Value
Collegium Pharmaceutical, Inc. (a) 14,107 $380,818
Corcept Therapeutics, Inc. (a) 41,247 2,964,834
CorMedix, Inc. (a) 26,590 244,362
Edgewise Therapeutics, Inc. (a) 20,643 338,545
Elanco Animal Health, Inc. (a) 218,059 2,067,199
Eli Lilly & Co. 353,769 318,020,643
Enliven Therapeutics, Inc. (a) 9,279 175,744
Evolus, Inc. (a) 20,556 234,338
EyePoint Pharmaceuticals, Inc. (a) 26,794 182,735
Harmony Biosciences Holdings, Inc. (a) 18,743 552,356
Harrow, Inc. (a) 13,137 325,404
Innoviva, Inc. (a) 24,364 455,363
Jazz Pharmaceuticals PLC (a) 25,172 2,944,117
Johnson & Johnson 1,055,545 164,992,239
Ligand Pharmaceuticals, Inc. (a) 8,327 914,804
Liquidia Corp. (a) 22,161 309,589
Merck & Co., Inc. 1,109,033 94,489,612
Mind Medicine MindMed, Inc. (a) 23,776 151,929
Nuvation Bio, Inc. (a) 94,718 213,116
Ocular Therapeutix, Inc. (a) 40,758 338,291
Organon & Co. 113,628 1,469,210
Pacira BioSciences, Inc. (a) 19,895 535,176
Perrigo Co. PLC 60,280 1,550,402
Pfizer, Inc. 2,484,515 60,647,011
Phathom Pharmaceuticals, Inc. (a) 16,406 70,382
Phibro Animal Health Corp. Class A 8,948 166,522
Pliant Therapeutics, Inc. (a) 21,625 34,384
Prestige Consumer Healthcare, Inc. (a) 21,681 1,761,148
Rapport Therapeutics, Inc. (a) 7,218 82,646
Royalty Pharma PLC Class A 165,486 5,431,251
Scilex Holding Co. (a) 998 4,729
Septerna, Inc. (a) 6,803 47,349
SIGA Technologies, Inc. 19,595 108,164
Supernus Pharmaceuticals, Inc. (a) 24,180 785,366
Tarsus Pharmaceuticals, Inc. (a) 12,565 652,249
Tilray Brands, Inc. (a) 409,080 198,445
Viatris, Inc. 522,026 4,395,459
WaVe Life Sciences Ltd. (a) 43,433 335,303
Zoetis, Inc. 197,798 30,935,607
TOTAL PHARMACEUTICALS 747,643,780
TOTAL COMMON STOCKS
(Cost $2,138,905,459)
2,562,698,009
5 Quarterly Report 

Schedule of Investments (Unaudited)continued
Money Market Fund – 0.2%
    Shares Value
State Street Institutional Treasury Plus Money Market Fund, Trust Class, 4.22% (b)
(Cost $5,844,000)
5,844,000 $5,844,000
TOTAL INVESTMENT IN SECURITIES – 99.9%
(Cost $2,144,749,459)
2,568,542,009
NET OTHER ASSETS (LIABILITIES) (c) – 0.1% 3,287,036
NET ASSETS – 100.0% $2,571,829,045
    
Legend  
(a) Non-income producing.
(b) The rate quoted is the annualized seven-day yield of the fund at period end.
(c) Includes $529,126 of cash collateral to cover margin requirements for futures contracts.
 
Futures Contracts
  Number of
contracts
Expiration
Date
Notional
Amount
Value Unrealized
Appreciation/
(Depreciation)
Purchased          
Equity Index Contracts          
CME E-mini Health Care Select Sector Index Contracts (United States) 56 June 2025 7,978,320 (135,701) (135,701)
CME E-mini Russell 2000 Index Contracts (United States) 8 June 2025 787,920 (9,750) (9,750)
Total Equity Index Contracts         $(145,451)
The notional amount of futures purchased as a percentage of Net Assets is 0.3%
Investment Valuation
Investments are valued as of 4:00 p.m. Eastern time on the last calendar day of the period. Securities transactions are accounted for as of trade date. The Board of Trustees (the Board) has designated the Fund's investment adviser as the valuation designee responsible for the fair valuation function and performing fair value determinations as needed. The investment adviser has established a Fair Value Committee (the Committee) to carry out the day-to-day fair valuation responsibilities and has adopted policies and procedures to govern the fair valuation process and the activities of the Committee. In accordance with these fair valuation policies and procedures, which have been approved by the Board, the Fund attempts to obtain prices from one or more third party pricing services or brokers to value its investments. When current market prices, quotations or currency exchange rates are not readily available or reliable, investments will be fair valued in good faith by the Committee, in accordance with the policies and procedures. Factors used in determining fair value vary by investment type and may include market or investment specific events, transaction data, estimated cash flows, and market observations of comparable investments. The frequency that the fair valuation procedures are used cannot be predicted and they may be utilized to a significant extent. The Committee manages the Fund's fair valuation practices and maintains the fair valuation policies and procedures. The Fund's investment adviser reports to the Board information regarding the fair valuation process and related material matters.
The inputs to valuation techniques used to value investments are categorized into a disclosure hierarchy consisting of three levels as shown below:
Level 1 – unadjusted quoted prices in active markets for identical investments
Level 2 – other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, etc.)
Level 3 – unobservable inputs (including the Fund's own assumptions based on the best information available)
Valuation techniques used to value investments by major category are as follows:
Equity securities, including restricted securities, for which market quotations are readily available, are valued at the last reported sale price or official closing price as reported by a third party pricing service on the primary market or exchange on which they are traded and are categorized as Level 1 in the hierarchy. In the event there were no sales during the day or closing prices are not available, securities are valued at the last quoted bid price or may be valued using the last available price and are generally categorized as Level 2 in the hierarchy. For any foreign equity securities, when market or security specific events arise, comparisons to the valuation of American Depositary Receipts (ADRs), futures contracts, Exchange-Traded Funds (ETFs) and certain indexes as well as quoted prices for similar securities may be used and would be categorized as Level 2 in the hierarchy. For equity securities, including restricted securities, where observable inputs are limited, assumptions about market activity and risk are used and these securities may be categorized as Level 3 in the hierarchy.
Futures contracts are valued at the settlement price established each day by the board of trade or exchange on which they are traded and are categorized as Level 1 in the hierarchy. Investments in any open-end mutual funds are valued at their closing net asset value (NAV) each business day and are categorized as Level 1 in the hierarchy. If an unaffiliated open-end mutual fund’s NAV is unavailable, shares of that fund may be valued by another method that the Board believes reflects fair value in accordance with the Board’s fair value pricing policies and is categorized as Level 2 in the hierarchy.
 Quarterly Report 6

Changes in valuation techniques may result in transfers in or out of an assigned level within the disclosure hierarchy.
Derivative Instruments
Risk Exposures and the Use of Derivative Instruments: The Fund's investment objectives allow the Fund to enter into various types of derivative contracts. Derivatives are investments whose value is primarily derived from underlying assets, indices or reference rates and may be transacted on an exchange or over-the-counter (OTC). Derivatives may involve a future commitment to buy or sell a specified asset based on specified terms, to exchange future cash flows at periodic intervals based on a notional principal amount, or for one party to make one or more payments upon the occurrence of specified events in exchange for periodic payments from the other party.
The Fund used derivatives to increase returns, to gain exposure to certain types of assets and/or to manage exposure to certain risks as defined below. The success of any strategy involving derivatives depends on analysis of numerous economic factors, and if the strategies for investment do not work as intended, the Fund may not achieve its objectives.
The Fund's use of derivatives increased or decreased its exposure to the following risk(s):
Equity Risk - Equity risk relates to the fluctuations in the value of financial instruments as a result of changes in market prices (other than those arising from interest rate risk or foreign exchange risk), whether caused by factors specific to an individual investment, its issuer, or all factors affecting all instruments traded in a market or market segment.
Investing in derivatives may involve greater risks than investing in the underlying assets directly and, to varying degrees, may involve risk of loss in excess of any initial investment and collateral received. In addition, there may be the risk that the change in value of the derivative contract does not correspond to the change in value of the underlying instrument.
Futures Contracts: A futures contract is an agreement between two parties to buy or sell a specified underlying instrument for a specified price at a specified future date.
The Fund used futures contracts to manage its exposure to the stock market.
Open futures contracts at period end are presented in the Schedule of Investments under the caption "Futures Contracts". The underlying face amount at value reflects each contract's exposure to the underlying instrument or index at period end. Any securities and/or cash deposited to meet initial margin requirements are identified in the Schedule of Investments.
For additional information on the Fund’s significant accounting policies, please refer to the Fund’s most recent semiannual or annual shareholder report.
7 Quarterly Report 

The fund’s schedule of investments as of the date on the cover of this report has not been audited. This report is provided for the general information of the fund’s shareholders. For more information regarding the fund and its holdings, please see the fund’s most recent prospectus and annual report.
Third party trademarks and service marks are the property of their respective owners. All other trademarks and service marks are the property of FMR LLC or an affiliate.     
 Quarterly Report 8